A Study to Observe the Safety, Tolerability, and Efficacy of Remodulin

Sponsor
Excelsior
Study ID
NCT06603285
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Pulmonary Arterial Hypertension

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Treprostinil — DRUG
    sc/iv continuously

Study Details

This is a multi-center, single-arm, prospective study to enroll patients diagnosed as pulmonary arterial hypertension. The objective in this study is to observe the efficacy and safety of treprostinil in subjects with pulmonary arterial hypertension.

Key Dates

First listed
Sep 19, 2024
Start date
Oct 16, 2025
Status verified
Aug 2025
Primary completion
May 31, 2029
Completion
Dec 31, 2029

Study Design

Enrollment
20 participants (estimated)

Primary Outcome Measure

Change from baseline in NT-proBNP [ Time Frame: Week 97 ]

Central Contacts

Related Studies